Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S ALLEGRA ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S ALLEGRA ALLERGY.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CHILDREN'S ALLEGRA ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Category A/B
Category C
Antihistamine
Antihistamine